Exopharm

By

On August 26 we presented our Science Webinar with Dr Jennifer King and Dr Anna Cifuentes-Rius about overcoming the delivery challenge for nucleic acid drugs. Deputy CEO & Chief Commercial Officer, Dr Chris Baldwin hosted the event and there was Q&A at the end of the presentations. After the technical and scientific questions were answered, Dr Chris Baldwin and CEO Dr Ian Dixon were on hand to address business-related questions relating to Exopharm.

We would like to thank our presenters Dr King and Dr Cifuentes-Rius for their engaging presentations and insights into nucleic acids and drug delivery and to our audience members for asking some interesting questions and engaging in the live webinar. We hope you enjoy the replay. To access the presentation slides, click here.

Watch the Replay on Vimeo

 

Topics

RNA Medicines and Delivery: The Importance for the Future of Medicine
Dr Jennifer King
King BioConsulting

Nucleic acid medicines are making the news and receiving marketing approvals in major jurisdictions. Dr Jennifer King discussed how pharmaceutical therapies have evolved from small molecule drugs to these nucleic acid-based medicines, and the promise that this emerging class of therapies holds for treating human disease.

Delivery by LNPs and Exosomes: When They Are Useful and Why

Dr Anna Cifuentes-Rius
Monash University

Despite the promise of nucleic acid therapies, their delivery within the body remains a major challenge. Dr Anna Cifuentes Rius discussed how the industry is working to use synthetic lipid-based nanoparticles to improve delivery, as well as the areas where exosomes, i.e. nanoparticles of biological origin, can overcome the limitations of their synthetic counterparts.

About the Presenters

Dr Jennifer King

Jennifer King, a Principal at King BioConsulting, has over 20 years of operating experience in the biopharmaceutical industry.  King BioConsulting provides business development and strategic support for biotechnology companies and other key stakeholders, with a focus on cutting edge technologies and orphan indications.  From 2015 to 2019 Jenn served at Intellia Therapeutics, a CRISPR Cas9 genome editing start-up, completing her tenure as Senior Vice President for Business Development.

Prior to her joining Intellia in 2015, Jenn held the position of Senior Director of Business Development at Shire Plc, (now Takeda) where she was responsible for the sourcing, initial evaluation and negotiation of licensing and acquisition opportunities within the company’s corporate development group. Before joining Shire in 2006, Jennifer held a variety of commercial roles in at Millennium Pharmaceuticals; most notably as the Product Manager for the US launch of VELCADE®.

Jennifer received her B.S. in Biology from the Massachusetts Institute of Technology, earned a Ph.D. in Developmental Biology at the Stanford University School of Medicine, and was awarded her MBA by Northeastern University.  In addition to a passion for biology and the biopharmaceutical industry, Jenn is an avid sailor and world traveller, and just completed her 100th scuba dive.

Dr Anna Cifuentes-Rius
Dr Anna Cifuentes-Rius is an NHMRC Early Career Fellow at Monash University. She has established an international and multidisciplinary research program with a focus on both fundamental and applied nanomedicine. Her research aims to understand the interactions between drug delivery systems and biological tissues with the ultimate goal of improving current therapy and diagnostic approaches. She has been trained at the Massachusetts Institute of Technology, University of Queensland, and University of South Australia. In 2013, she completed her PhD at Institut Quimic de Sarria (Ramon Llull University, Barcelona). Among her passions are empowering young researchers and promoting equitable leadership in science.